Rosewind CORP just filed a prospectus, suggesting it plans to soon issue some securities

Rosewind CORP just came out with a new prospectus, available here. This is an SEC requirement for firms looking to issue certain types of securities. An excerpt of the prospectus is provided below:

424B3 1 v464470_424b3.htm 424B3   Prospectus Supplement filed pursuant to Rule 424(b)(3) in connection with Registration Statement No. 333-213489     Aytu BioScience, Inc.   Prospectus Supplement No. 2 dated April 18, 2017 (to Prospectus dated April 4, 2017)   1,076,596 shares of common stock     This Prospectus Supplement No. 1 updates, amends, and supplements the information previously included in our prospectus dated April 4, 2017, which we refer to as our prospectus, relating to the offer for sale or other disposition of an aggregate of 1,076,596 shares of common stock, $0.0001 par value per share, of Aytu BioScience, Inc., issued and issuable to Lincoln Park Capital Fund, LLC, the selling shareholder named in the prospectus.   Material Information Reported in Current Report on Form 8-K   On April 18, 2017, we filed a Current Report on Form 8-K to report the entry into employment agreements with each of Joshua R. Disbrow and Jarrett T. Disbrow. The material portions of that Form 8-K are set forth below.     On April 14, 2017, we entered into an employment agreement with each of Joshua R. Disbrow and Jarrett T. Disbrow, each effective April 16, 2017. The agreements are identical, except for the positon that each executive is to occupy, and are identical to the two-year employment agreements entered into effective April 16, 2015. Joshua Disbrow is currently our Chief Executive Officer and Jarrett Disbrow is currently our Chief Operating Officer. Each will occupy the same position during the term of his respective agreement, and Joshua Disbrow will also serve as our Chairman of the Board during the term of his agreement.   Each agreement is for a term of 24 months beginning on April 16, 2017, subject to termination by us with or without Cause (as defined below) or as a result of the officer’s disability, or by the officer with or without Good Reason (as defined below). Each officer is entitled to receive $250,000 in annual salary, plus a discretionary performan

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Rosewind CORP makes a similar move, sign up!

Other recent filings from the company include the following:

Additional definitive proxy soliciting materials and Rule 14(a)(12) material - May 14, 2018
Other preliminary proxy statements - April 27, 2018

Auto Refresh